_id
691308cbccc777a4e85d7b82
Ticker
KAPA
Name
Kairos Pharma, Ltd.
Exchange
NYSE MKT
Address
2355 Westwood Boulevard, Los Angeles, CA, United States, 90064
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://kairospharma.com
Description
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Last Close
0.703
Volume
75477
Current Price
0.9355
Change
0.0193
Last Updated
2026-01-04T15:53:52.636Z
Image
data:image/webp;base64,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
Ipo Date
2024-09-16T00:00:00.000Z
Market Cap
15128428
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4.3333
Target Price
8.3333
Strong Buy
1
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
40000
Gross Profit
-40000
Operating Expenses
1325000
Operating Income
-1365000
Interest Expense
0
Pretax Income
-1398000
Net Income
-1398000
Eps
-0.06918725709296822
Dividends Per Share
-
Shares Outstanding
20743765
Income Tax Expense
-
EBITDA
-1358000
Operating Margin
-
Total Other Income Expense Net
-33000
Cash
5575000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
6656000
Property Plant Equipment
-
Total Assets
8066000
Payables
-
Short Term Debt
-
Long Term Debt
-
Total Liabilities
402000
Equity
7664000
Bs_currency_symbol
USD
Depreciation
40000
Change In Working Capital
-210000
Cash From Operations
-838000
Capital Expenditures
838000
Cash From Investing
-
Cash From Financing
3379000
Net Change In Cash
2541000
Cf_currency_symbol
USD
PE
-
PB
2.4664331773877874
ROE
-18.24112734864301
ROA
-17.33201090999256
FCF
-1676000
Fcf Percent
-
Piotroski FScore
1
Health Score
43
Deep Value Investing Score
4.5
Defensive Investing Score
5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
3
Net Net Investing Score
3
Quality Investing Score
3
Value Investing Score
5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
40000
Quarters > 0 > income Statement > gross Profit
-40000
Quarters > 0 > income Statement > operating Expenses
1325000
Quarters > 0 > income Statement > operating Income
-1365000
Quarters > 0 > income Statement > interest Expense
0
Quarters > 0 > income Statement > pretax Income
-1398000
Quarters > 0 > income Statement > net Income
-1398000
Quarters > 0 > income Statement > eps
-0.06918725709296822
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
20206033
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-1358000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-33000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
5575000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
6656000
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
8066000
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
402000
Quarters > 0 > balance Sheet > equity
7664000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-1398000
Quarters > 0 > cash Flow > depreciation
40000
Quarters > 0 > cash Flow > change In Working Capital
-210000
Quarters > 0 > cash Flow > cash From Operations
-838000
Quarters > 0 > cash Flow > capital Expenditures
838000
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
3379000
Quarters > 0 > cash Flow > net Change In Cash
2541000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.06918725709296822
Quarters > 0 > ratios > PB
2.4664331773877874
Quarters > 0 > ratios > ROE
-18.24112734864301
Quarters > 0 > ratios > ROA
-17.33201090999256
Quarters > 0 > ratios > FCF
-1676000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
43
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
40000
Quarters > 1 > income Statement > gross Profit
-40000
Quarters > 1 > income Statement > operating Expenses
1338000
Quarters > 1 > income Statement > operating Income
-1378000
Quarters > 1 > income Statement > interest Expense
0
Quarters > 1 > income Statement > pretax Income
-1422000
Quarters > 1 > income Statement > net Income
-1422000
Quarters > 1 > income Statement > eps
-0.08261189772832966
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
17213017
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-1382000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-44000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
3034000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
4839000
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
6673000
Quarters > 1 > balance Sheet > payables
676000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
676000
Quarters > 1 > balance Sheet > equity
5997000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-1422000
Quarters > 1 > cash Flow > depreciation
40000
Quarters > 1 > cash Flow > change In Working Capital
-798000
Quarters > 1 > cash Flow > cash From Operations
-805000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
223000
Quarters > 1 > cash Flow > net Change In Cash
-582000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.08261189772832966
Quarters > 1 > ratios > PB
2.685138803318326
Quarters > 1 > ratios > ROE
-23.71185592796398
Quarters > 1 > ratios > ROA
-21.309755732054548
Quarters > 1 > ratios > FCF
-805000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
43
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
40000
Quarters > 2 > income Statement > gross Profit
-40000
Quarters > 2 > income Statement > operating Expenses
1226000
Quarters > 2 > income Statement > operating Income
-1266000
Quarters > 2 > income Statement > interest Expense
133000
Quarters > 2 > income Statement > pretax Income
-1262000
Quarters > 2 > income Statement > net Income
-1262000
Quarters > 2 > income Statement > eps
-0.07949363436770593
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
15875485
Quarters > 2 > income Statement > income Tax Expense
-2603000
Quarters > 2 > income Statement > EBITDA
-1222000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
4000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
3616000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
6050000
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
7937000
Quarters > 2 > balance Sheet > payables
805000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
805000
Quarters > 2 > balance Sheet > equity
7132000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-1262000
Quarters > 2 > cash Flow > depreciation
40000
Quarters > 2 > cash Flow > change In Working Capital
432000
Quarters > 2 > cash Flow > cash From Operations
-714000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
3058000
Quarters > 2 > cash Flow > net Change In Cash
2344000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.07949363436770593
Quarters > 2 > ratios > PB
2.0823774842260234
Quarters > 2 > ratios > ROE
-17.694896242288277
Quarters > 2 > ratios > ROA
-15.900214186720424
Quarters > 2 > ratios > FCF
-714000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
43
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
1446000
Quarters > 3 > income Statement > operating Income
-1446000
Quarters > 3 > income Statement > interest Expense
0
Quarters > 3 > income Statement > pretax Income
-980000
Quarters > 3 > income Statement > net Income
-980000
Quarters > 3 > income Statement > eps
-0.07134226912240346
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
13736597
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
1272000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
4169000
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
5768000
Quarters > 3 > balance Sheet > payables
992000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
992000
Quarters > 3 > balance Sheet > equity
4776000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-980000
Quarters > 3 > cash Flow > depreciation
40000
Quarters > 3 > cash Flow > change In Working Capital
-610000
Quarters > 3 > cash Flow > cash From Operations
-1803000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-142000
Quarters > 3 > cash Flow > net Change In Cash
-1945000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.07134226912240346
Quarters > 3 > ratios > PB
2.690658813546901
Quarters > 3 > ratios > ROE
-20.519262981574542
Quarters > 3 > ratios > ROA
-16.990291262135923
Quarters > 3 > ratios > FCF
-1803000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
42
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
160000
Annuals > 0 > income Statement > gross Profit
-160000
Annuals > 0 > income Statement > operating Expenses
2183000
Annuals > 0 > income Statement > operating Income
-2343000
Annuals > 0 > income Statement > interest Expense
859000
Annuals > 0 > income Statement > pretax Income
-2603000
Annuals > 0 > income Statement > net Income
-2603000
Annuals > 0 > income Statement > eps
-0.22920893155793126
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
11356451
Annuals > 0 > income Statement > income Tax Expense
-2603000
Annuals > 0 > income Statement > EBITDA
-1584000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-260000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
1272000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
4168999
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
6216000
Annuals > 0 > balance Sheet > payables
992000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
1440000
Annuals > 0 > balance Sheet > equity
4776000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-2603000
Annuals > 0 > cash Flow > depreciation
160000
Annuals > 0 > cash Flow > change In Working Capital
-1984000
Annuals > 0 > cash Flow > cash From Operations
-3955000
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
5134000
Annuals > 0 > cash Flow > net Change In Cash
1179000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-0.22920893155793126
Annuals > 0 > ratios > PB
1.734141481218593
Annuals > 0 > ratios > ROE
-54.501675041876055
Annuals > 0 > ratios > ROA
-41.87580437580438
Annuals > 0 > ratios > FCF
-3955000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
35
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
160000
Annuals > 1 > income Statement > gross Profit
-160000
Annuals > 1 > income Statement > operating Expenses
1554000
Annuals > 1 > income Statement > operating Income
-1714000
Annuals > 1 > income Statement > interest Expense
98000
Annuals > 1 > income Statement > pretax Income
-1812000
Annuals > 1 > income Statement > net Income
-1812000
Annuals > 1 > income Statement > eps
-0.17452418802188102
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
10382515
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-1554000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-98000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
93000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
101000
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
965000
Annuals > 1 > balance Sheet > payables
2401000
Annuals > 1 > balance Sheet > short Term Debt
4000
Annuals > 1 > balance Sheet > long Term Debt
638000
Annuals > 1 > balance Sheet > total Liabilities
3043000
Annuals > 1 > balance Sheet > equity
-2078000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-1812000
Annuals > 1 > cash Flow > depreciation
160000
Annuals > 1 > cash Flow > change In Working Capital
764000
Annuals > 1 > cash Flow > cash From Operations
81000
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
-425000
Annuals > 1 > cash Flow > net Change In Cash
-344000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.17452418802188102
Annuals > 1 > ratios > PB
-3.643873045957651
Annuals > 1 > ratios > ROE
87.19923002887391
Annuals > 1 > ratios > ROA
-187.77202072538861
Annuals > 1 > ratios > FCF
81000
Annuals > 1 > ratios > Piotroski FScore
2
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
50
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
160000
Annuals > 2 > income Statement > gross Profit
-160000
Annuals > 2 > income Statement > operating Expenses
411000
Annuals > 2 > income Statement > operating Income
-571000
Annuals > 2 > income Statement > interest Expense
479000
Annuals > 2 > income Statement > pretax Income
-1050000
Annuals > 2 > income Statement > net Income
-1050000
Annuals > 2 > income Statement > eps
-0.10257147668931314
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
10236764
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-411000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-479000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
437000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
437000
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
1036000
Annuals > 2 > balance Sheet > payables
1629000
Annuals > 2 > balance Sheet > short Term Debt
4000
Annuals > 2 > balance Sheet > long Term Debt
582000
Annuals > 2 > balance Sheet > total Liabilities
2215000
Annuals > 2 > balance Sheet > equity
-1179000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-1050000
Annuals > 2 > cash Flow > depreciation
160000
Annuals > 2 > cash Flow > change In Working Capital
129000
Annuals > 2 > cash Flow > cash From Operations
-353000
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
717000
Annuals > 2 > cash Flow > net Change In Cash
364000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.10257147668931314
Annuals > 2 > ratios > PB
-6.332206942493638
Annuals > 2 > ratios > ROE
89.05852417302799
Annuals > 2 > ratios > ROA
-101.35135135135135
Annuals > 2 > ratios > FCF
-353000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
31
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
98000
Annuals > 3 > income Statement > gross Profit
-98000
Annuals > 3 > income Statement > operating Expenses
1845000
Annuals > 3 > income Statement > operating Income
-1943000
Annuals > 3 > income Statement > interest Expense
202000
Annuals > 3 > income Statement > pretax Income
-2145000
Annuals > 3 > income Statement > net Income
-2145000
Annuals > 3 > income Statement > eps
-0.16703087703981104
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
12841937
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-1845000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-202000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
73000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
73000
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
775000
Annuals > 3 > balance Sheet > payables
1548000
Annuals > 3 > balance Sheet > short Term Debt
380000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
1942000
Annuals > 3 > balance Sheet > equity
-1167000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-2145000
Annuals > 3 > cash Flow > depreciation
98000
Annuals > 3 > cash Flow > change In Working Capital
1191000
Annuals > 3 > cash Flow > cash From Operations
-412000
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-109000
Annuals > 3 > cash Flow > cash From Financing
580000
Annuals > 3 > cash Flow > net Change In Cash
59000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.16703087703981104
Annuals > 3 > ratios > PB
-8.025385307712082
Annuals > 3 > ratios > ROE
183.80462724935734
Annuals > 3 > ratios > ROA
-276.7741935483871
Annuals > 3 > ratios > FCF
-412000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
31
Valuation > metrics > PE
-0.06918725709296822
Valuation > metrics > PB
2.4664331773877874
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-18.24112734864301
Profitability > metrics > ROA
-21.003605769230766
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.052453027139874736
Risk > metrics > Interest Coverage
-34.125
Risk > final Score
-76
Risk > verdict
High
Liquidity > final Score
50
Liquidity > verdict
Weak
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-78
Prev Risks > 1
22
Prev Risks > 2
80
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:05:12.228Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-12-03
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.07
Earnings History > 0 > eps Estimate
-0.075
Earnings History > 0 > eps Difference
0.005
Earnings History > 0 > surprise Percent
6.6667
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-09-03
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.065
Earnings History > 1 > eps Estimate
-0.05
Earnings History > 1 > eps Difference
-0.015
Earnings History > 1 > surprise Percent
-30
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-28
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.08
Earnings History > 2 > eps Estimate
-0.05
Earnings History > 2 > eps Difference
-0.03
Earnings History > 2 > surprise Percent
-60
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-02-26
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.05
Earnings History > 3 > eps Estimate
-0.02
Earnings History > 3 > eps Difference
-0.03
Earnings History > 3 > surprise Percent
-150
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-27
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.05
Earnings History > 4 > eps Estimate
-0.02
Earnings History > 4 > eps Difference
-0.03
Earnings History > 4 > surprise Percent
-150
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-28
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
-0.02
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.02
Earnings History > 5 > surprise Percent
-
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ARSI Check: Is JX Luxventure Group Inc backed by strong institutional buying - July 2025 Update & Advanced Swing Trade Entry Alerts baoquankhu1.vn
Read more →Stock Report: What is the implied volatility of Fly E Group Inc - Trade Analysis Summary & High Yield Equity Trading Tips baoquankhu1.vn
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$8.3333
Analyst Picks
Strong Buy
1
Buy
2
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Kairos Pharma, Ltd.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.07
EPS Estimate
-0.075
EPS Difference
0.005
Surprise Percent
6.6667%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.